While the majority of people with type 2 diabetes (T2D) do not have established cardiovascular disease (CVD), most are at risk for a cardiovascular (CV) event. In recognition of this significant risk, international and local guidelines recommend that the focus of T2D management move beyond glycaemic control to include comprehensive CV risk management. According to these guidelines, GLP-1 receptor agonists indicated for cardioprotection should now be considered in patients with T2D and established CV disease or in those without established CVD but with multiple CV risk factors.
This 1-hour RACGP accredited activity aims to enable GPs to confidently select patients with T2D who might benefit from initiation of a GLP-1 receptor agonist as first injectable therapy.
This program is supported by an independent educational grant provided from Eli Lilly.